Clinical symptoms:

The objective of therapeutic apheresis using immunoadsorbers is to remove pathogenic antibodies or auto-antibodies and circulating immune complexes from the patient’s plasma. These are very significant in the progress of immunological diseases. Immunoadsorption is therefore used as a therapeutic measure in the treatment of some autoimmune diseases or antibody-mediated transplant rejection. The adsorber systems used in immunoadsorption can differ, among other things, in their ligands and other characteristics. Fresenius Medical Care Adsorber Tec GmbH produces 4 different kinds of immunoadsorber. All of these can only be used with plasma, so the plasma must always be separated before they are used. (Source: Fresenius brochure “Immunoadsorption in dilated cardiomyophathy (DCM)” and “Globaffin – the first synthetic broadband immunoadsorber”)

Adsorber: GLOBAFFIN®

GLOBAFFIN® is the first synthetic broadband immunoadsorber and contains the synthetic peptide GAM® as a ligand. It is thus completely free of animal materials. The peptide has a high binding affinity with antibodies (mainly IgG-class). Two adsorbers always work in alternation during the treatment in order to remove as many antibodies as possible. While one adsorbs, the other desorbs (= regenerates) and vice versa. This regeneration can take place as often as needed during treatment. After treatment, the adsorbers are preserved and used on the same patient as often as needed. (Source: Fresenius brochure “Globaffin – the first synthetic broadband immunoadsorber”)